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Progression of acute myeloid leukaemia (AML) ± the most severe blood/bone marrow cancer 23 
± is determined by the ability of malignant cells to escape host immune surveillance. 24 
However, the systemic regulation mechanisms underlying this phenomenon remain largely 25 
unknown. In this study we have discovered a fundamental systemic biochemical strategy 26 
which allows AML cells to employ physiological body systems to survive and escape 27 
immune attack. We found that AML cells use a crucial human adrenal cortex hormone 28 
(cortisol) to induce the expression of the neuronal receptor latrophilin 1 (LPHN1) which 29 
facilitates exocytosis. This receptor interacts with the blood plasma protein FLRT3 30 
(fibronectin leucine rich transmembrane protein 3) to cause secretion of the immune 31 
suppressor galectin-9 which impairs the anti-cancer activities of cytotoxic lymphoid cells. 32 
AML is a cancer of the blood and bone marrow which originates from self-renewing 33 
malignant immature myeloid cells and rapidly becomes a systemic, and very often fatal, 34 
malignancy1. AML cells employ body systems to produce factors required for their 35 
proliferation/disease progression2,3. This includes employment of stem cell factor (SCF), a 36 
major hematopoietic growth factor controlling AML progression and thus becoming highly 37 
oncogenic2,3. Expression and release of SCF can be triggered by AML cells via cytokines 38 
(e.g. interleukin-ȕ2. Recent evidence clearly demonstrated that AML cells are also capable 39 
of impairing the activities of cytotoxic lymphoid cells (e.g. natural killer (NK) cells and 40 
cytotoxic T cells4). One of the biochemical mechanisms underlying this phenomenon lies in 41 
the ability of AML cells to secrete the protein called galectin-9. This tandem type galectin 42 
binds the immune receptor Tim-3 and induces a variety of intracellular and cell-to-cell 43 
signalling events leading to the inactivation of NK cells as well as killing of cytotoxic T 44 
cells4,5. We recently reported that the process of galectin-9 secretion in AML cells is 45 
stimulated by the unique G protein-coupled receptor LPHN1, which normally functions in 46 
neurons facilitating exocytosis4,6. LPHN1 is also found in haematopoietic stem cells (HSCs) 47 
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but its expression disappears at early stages of their maturation4,7. However, upon malignant 48 
transformation, AML cells preserve their abilities to express LPHN1 and produce high levels 49 
of galectin-9 and Tim-3, where the latter is involved in trafficking galectin-9 during the 50 
secretion process (HSCs express neither galectin-9 nor Tim-34).  51 
It is currently unknown which molecular mechanisms trigger high levels of LPHN1 52 
expression in primary human AML cells, and in general mechanisms of upregulation of 53 
LPHN1 expression at the genomic level remain unclear. It is also unknown whether FLRT3, 54 
a natural LPHN1 ligand4,8, is present in human blood plasma and other tissues associated 55 
with AML. Unravelling these mechanisms is crucial in order to understand the pathways that 56 
control the ability of AML cells to protect themselves against cytotoxic lymphoid cells and 57 
thus was the aim of the present study. 58 
Results and Discussion 59 
In order to investigate the effects of cortisol on LPHN1 transcription, we exposed primary 60 
and THP-1 human AML cells, primary human HSCs and primary healthy human leukocytes 61 
to 1 µM cortisol for 24 h followed by quantitative real-time PCR analysis of LPHN1 mRNA 62 
levels. We found that all cell types, except primary healthy leukocytes, transcribed detectable 63 
amounts of LPHN1 mRNA and in all these cases levels were significantly upregulated by 64 
treatment with cortisol (Figure 1A). In both THP-1 and primary human AML cells LPHN1 65 
protein levels were also clearly upregulated (Figure 1B and C). In contrast, primary human 66 
healthy leukocytes did not express detectable amounts of LPHN1 protein and this was not 67 
altered by the effects of cortisol (Figure 1D). Comparative analysis of LPHN1 protein 68 
expression in primary human AML cells, THP-1 cells and primary human healthy leukocytes 69 
is shown in Supplementary figure 1.  70 
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Cortisol treatments did not upregulate galectin-9 secretion in any of these cell types (Figure 1 71 
B-D), suggesting that LPHN1 needs to be activated by a ligand to induce galectin-9 release. 72 
Analysis of blood plasma levels of cortisol in AML patients vs healthy donors (samples were 73 
collected at the same time of the day to avoid the influence of circadian dynamics) 74 
demonstrated that its levels were significantly higher in the blood plasma of AML patients 75 
compared to healthy donors (Figure 1E). Galectin-9 levels were also substantially higher in 76 
AML patients (Figure 1F), which is in line with our previous observations4. Furthermore, 77 
there was no correlation between cortisol and galectin-9 levels in the blood plasma of healthy 78 
donors, while in AML patients there was a clear correlation (Figure 1G), suggesting that 79 
galectin-9 secretion in this case might be linked to LPHN1 expression.  80 
If LPHN1 is expressed on the surface of blood cells, it can also be shed by proteolysis and 81 
therefore appear in the plasma. LPHN1 was immunoprecipitated, extracted and subjected to 82 
Western blot analysis from blood plasma samples from AML patients using several LPHN1 83 
antibodies. A clear fragment was detectable at around 67-68 kDa, smaller fragments were 84 
detectable as well, but only in AML plasma, while in the blood plasma of healthy donors 85 
there was no evidence of the presence of LPHN1 fragments (Figure 1H). These fragments 86 
were also detectable by ELISA (Figure 1I, see Materials and Methods for description of the 87 
ELISA format).  88 
As reported before4, we observed that exposure of THP-1 AML cells to 10 nM FLRT3 for 16 89 
h resulted in a significant increase in galectin-9 secretion (Figure 2A). This effect was not 90 
detectable in primary healthy human leukocytes (Figure 2A). Importantly, 1 h pre-exposure 91 
of THP-1 cells to rabbit polyclonal antibody recognising LPHN1 (clone name RL19) prior to 92 
16 h treatment with 10 nM FLRT3 attenuated FLRT3-induced galectin-9 release, confirming 93 
involvement of LPHN1 in this process (Figure 2A). The antibody employed specifically 94 
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recognised target molecules on the surface of THP-1 cells (Supplementary figure 2). We used 95 
mouse neuroblastoma cells NB2A, which do not express LPHN110, as a negative control and 96 
measured the interaction of the antibody with the cell surface using a Li-Cor on-cell assay as 97 
described in the Materials and Methods (please see supplementary information). Exposure of 98 
THP-1 cells to 1 µg/ml RL1 for 16 h did not affect galectin-9 secretion levels (data not 99 
shown) suggesting that this antibody lacks a LPHN1 agonistic effect.  100 
Interestingly, we found that blood plasma of both healthy donors and AML patients contains 101 
approximately equal amounts of secreted FLRT3 (most likely by proteolytic shedding) with a 102 
molecular weight of approximately 55 kDa (which corresponds to the molecular weight of 103 
FLRT3 shed from the cell surface by proteinases11). Another specific band was seen at 104 
around 27-28 kDa which most likely corresponds to a smaller cleavage fragment of the 105 
FLRT3 extracellular domain (Figure 2B). The amounts of this smaller fragment were also 106 
equal in blood plasma of healthy donors and AML patients (Figure 2B). To explore which 107 
blood plasma-based ligands can induce galectin-9 secretion in AML cells we cultured THP-1 108 
cells in RPMI-1640 medium containing antibiotics (as outlined in Materials and Methods ± 109 
see supplementary information) replacing 10 % foetal bovine serum (FBS) with blood plasma 110 
from either healthy donors or AML patients. Cells were incubated for 16 h with or without 30 111 
min pre-incubation with anti-FLRT3 antibody in order to neutralise FLRT3 activity. 112 
Galectin-9 secretion levels were significantly higher in the presence of both sources of human 113 
blood plasma compared to FBS (negative control). Anti-FLRT3 antibody attenuated galectin-114 
9 secretion (Figure 2C). Binding of LPHN1 and FLRT3 was further confirmed using SRCD 115 
spectroscopy. We found that the two proteins interact with each other with high affinity, 116 
inducing conformational change in both proteins, as seen from far UV synchrotron radiation 117 
circular dichroism (SRCD) spectra (Figure 2D). This is further confirmation of the high 118 
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affinity interaction of LPHN1 and FLRT3 observed in previous studies8 using different 119 
techniques.  120 
Taken together, our results demonstrate, for the first time, that cortisol upregulates LPHN1 121 
expression at the transcriptional level, thus stimulating its translation in human AML cells. 122 
AML leads to a decreased blood plasma glucose levels5, which normally leads to 123 
upregulation of secretion of corticotropin-releasing hormone (CTRH) by hypothalamus12. 124 
CTRH induces secretion of adrenocorticotropic hormone (ACTH) by pituitary gland12. 125 
ACTH upregulates cortisol production by the adrenal cortex12. Cortisol is then employed by 126 
AML cells. In healthy human leukocytes cortisol is not capable of inducing LPHN1 127 
transcription/translation, possibly because of gene repression. Interaction of AML cell-128 
derived LPHN1 with released FLRT3 available in blood plasma facilitates the secretion of 129 
galectin-9. The latter protects AML cells against immune attack which could otherwise be 130 
performed by NK cells as well as cytotoxic T cells (Supplementary figure 3). Importantly, 131 
LPHN1 fragments are present in the blood plasma of AML patients but not in healthy donors. 132 
These fragments were detectable by both Western blot analysis and ELISA, which indicates 133 
the possibility of detection of these fragments for rapid AML diagnosis, although differential 134 
verification tests have yet to be performed. Our results suggest a fundamentally novel 135 
mechanism used by AML cells in order to progress the disease. They use a common 136 
endogenous human hormone (cortisol) to induce LPHN1 expression by employing a widely 137 
available ligand (FLRT3, which is always present in blood plasma) in order to escape host 138 
immune surveillance. Thus, AML cells employ crucial functional systems of the human body 139 
to support their survival and attenuate the anti-cancer activities of cytotoxic lymphoid cells. 140 
Our work indicates that galectin-9 and secreted FLRT3 are the most promising targets for 141 





Materials and Methods are presented in Supplementary Information. 145 
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Figure legends.  215 
Figure 1. Cortisol induces LPHN1 expression in human AML cells and haematopoietic 216 
stem cells but not in primary healthy human leukocytes. Primary human AML, THP-1 217 
and haematopoietic stem cells as well as primary healthy leukocytes were exposed to 1 µM 218 
cortisol for 24 h followed by analysis of LPHN1 gene transcription by quantitative real-time 219 
PCR (A) and Western blot analysis (B ± primary AML cells, C ± THP-1 cells and D ± PHL). 220 
For PHL, lysates of LPHN1 overexpressing NB2A cells were used as a positive control. 221 
ELISA was used to measure secreted galectin-9 levels. Blood plasma of ten healthy donors 222 
and ten AML patients was collected at the same time of the day to ensure comparability of 223 
cortisol levels. Cortisol (E) and galectin-9 (F) levels were measured by ELISA and 224 
correlation between the levels of these two proteins was analysed (G). Soluble LPHN1 225 
fragments were immunoprecipitated and detected by Western blot (H) and ELISA (I), as 226 
outlined in Materials and Methods. Images are from one experiment representative of four ± 227 
six which gave similar results. Data represent mean values ± SEM of six ± ten independent 228 
experiments. ; *p < 0.05; **p < 0.01; ***p < 0.01 vs. control. 229 
 230 
Figure 2. FLRT3 induces galectin-9 secretion in AML cells in a LPHN1-dependent 231 
manner. THP-1 cells and PHL were exposed to 10 nM human recombinant FLRT3 for 16 h, 232 
followed by detection of secreted galectin-9 by ELISA. In THP-1 cells, the treatment was 233 
performed with or without 1 h pre-exposure to 1 µg/ml RL1 anti-LPHN1 polyclonal antibody 234 
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(A). The levels of released FLRT3 fragments were analysed in the blood plasma of healthy 235 
donors and AML patients using Western blot (B). THP-1 cells were exposed for 16 h to 10% 236 
blood plasma either from healthy donors or AML patients, with or without pre-treatment with 237 
FLRT3 neutralising antibody. Levels of secreted galectin-9 were analysed using ELISA. (C). 238 
Secondary structure and conformational changes of LPHN1, FLRT3 and the complex of the 239 
two proteins were characterised using SRCD spectroscopy as outlined in Materials and 240 
Methods (D). Images are shown from one representative experiment of four which gave 241 
similar results. Data are shown as mean values ± SEM from four independent experiments; 242 
*p < 0.05; **p < 0.01 vs. control. 243 
 244 
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Materials and Methods 276 
 277 
Materials 278 
RPMI-1640 medium, foetal bovine serum, supplements as well as basic laboratory chemicals 279 
were purchased from Sigma-$OGULFK 6XIIRON 8. 0D[LVRUS PLFURWLWUH SODWHV ZHUH280 
obtained from Nunc (Roskilde, Denmark) and Oxley Hughes Ltd (London, UK). Human 281 
recombinant FLRT3, mouse monoclonal antibody against LPHN1 and rabbit antibody against 282 
FLRT3 were purchased from Santa Cruz Biotechnology (Dallas, Texas, USA). PAL1 and 283 
RL1 rabbit polyclonal antibodies against LPHN1 were described previously1,2. Rabbit 284 
antibody against native LPHN1 was obtained from Abcam (Cambridge, UK). Goat anti-285 
mouse and goat anti-rabbit fluorescence dye-labelled antibodies were obtained from LI-COR 286 
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(Lincoln, Nebraska USA). ELISA-based assay kits for the detection of galectin-9 were 287 
purchased from Bio-Techne (R&D Systems, Abingdon, UK). A soluble extracellular 288 
fragment of LPHN1, LPH-51, was produced and purified as described before2. Briefly, NB2a 289 
cells stably expressing LPH-51 were cultured in serum-free medium for 48 h. 30 mL of the 290 
medium was then incubated overnight at 4°C with 500 ȝL of anti-V5-antibody agarose 291 
(Sigma-Aldrich). After incubation, the column was washed with 10 column volumes of PBS. 292 
Bound protein was fractionally eluted with 5 volumes of elution buffer containing 50 mM 293 
triethylamine and 150 mM NaCl (pH 12).  The eluted protein was immediately neutralized 294 
with 150 mM NaCl, 1 M HEPES (pH 7.2)9. The fractions were then analysed by Western 295 
blotting and combined. The protein was concentrated using Amicon centrifugal ultrafiltration 296 
units with a 30,000 molecular weight cut-off (Sigma-Aldrich). All other chemicals purchased 297 
were of the highest grade of purity commercially available. 298 
 299 
 300 
Cell lines and primary cells 301 
THP-1 human myeloid leukemia monocytes cells were obtained from the European 302 
Collection of Cell Cultures (Salisbury, UK). Cells were cultured in RPMI 1640 medium 303 
(R8758 ± Sigma-Aldrich) with L-glutamine and sodium bicarbonate, liquid, sterile-filtered, 304 
suitable for cell culture) supplemented with 10% foetal bovine serum, penicillin (50 IU/ml) 305 
and streptomycin sulphate (50 µg/ml). Untransfected mouse neuroblastoma cells (NB2A) and 306 
those overexpressing the full-size LPHN1 (LPH-42) were handled as described earlier9.  307 
Primary human AML cells were obtained from the sample bank of the University Medical 308 
Centre Hamburg-Eppendorf (Ethik-Kommission der Ärztekammer Hamburg, reference: 309 
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PV3469). Cells were incubated in IMDM medium containing 15% BIT 9500 serum 310 
substitute, 100 µM mercaptoethanol, 100 ng/ml stem cell factor (SCF), 50 ng/ml FLT3, 20 311 
ng/ml G-CSF, 20 ng/ml IL-3, 1 µM UM729 and 500 nM stemregenin 1 (SR1) as described 312 
before3. 313 
Primary human blood plasma samples 314 
Blood plasma from healthy donors was generated by centrifugation of peripheral blood 315 
provided by the National Health Blood and Transfusion Service (NHSBT, UK) following 316 
ethical approval (REC reference: 16-SS-033). Primary human AML plasma samples were 317 
obtained from the sample bank of University Medical Centre Hamburg-Eppendorf (Ethik-318 
Kommission der Ärztekammer Hamburg, reference: PV3469)4. 319 
Western blot analysis 320 
LPHN1 protein levels were analysed using Western blotting. ȕ-actin staining was used to 321 
confirm equal protein loading as described previously (4, 6, 14). LI-COR goat secondary 322 
antibodies (dilution 1:2000), conjugated with fluorescent dyes, were used in accordance with 323 
manufacturer's protocol to visualise target proteins (using a LI-COR Odyssey imaging 324 
system). Western blot data were quantitatively analysed using Odyssey software and values 325 
were subsequently normalised against those of ȕ-actin1,4,5.  326 
Enzyme-linked immunosorbent assays (ELISAs) and immunoprecipitation 327 
Secreted galectin-9 was measured by ELISA using R&D Systems kits according to 328 
PDQXIDFWXUHU¶s protocol. Plasma cortisol was measured by ELISA using the Salimetrics assay 329 
NLWDFFRUGLQJWRWKHPDQXIDFWXUHU¶VSURWRFROV6DOLPHWULFV6XIIRON8. 330 
For immunoprecipitation of LPHN1 fragments from human blood plasma, plates were coated 331 
with mouse monoclonal LPHN1 antibody following the principle and protocol described 332 
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previously5. This was followed by blocking with 2% BSA. Samples were then applied and 333 
incubated for at least 4 h at room temperature after which plates were extensively washed 334 
with Tris buffered saline with Tween-20 (TBST). Glycine-HCl pH lowering buffer (pH 2.0) 335 
was then applied to extract the bound proteins. Extracts were mixed with equal volumes of 336 
lysis buffer (pH 7.5) and with 4× sample buffer for SDS-PAGE at a ratio of 1:3. Samples 337 
were then subjected to Western blot analysis (5), using rabbit PAL1 anti-LPHN1 antibody. 338 
Alternatively, PAL1 antibody was applied as detection antibody, followed by visualisation 339 
using HRP-labelled anti-rabbit secondary antibody (Abcam, Cambridge, UK).  340 
On cell assays  341 
We employed a standard LI-COR on cell assay to characterise interaction of RL-1 antibody 342 
with the surface of THP-1 cells4,5. 343 
 344 
 345 
Synchrotron radiation circular dichroism (SRCD) spectroscopy 346 
Human recombinant LPHN1 and FLRT3 were analysed, either alone or in combination with 347 
each other, using SRCD spectroscopy at beamline B23, Diamond Light Source (Didcot, UK). 348 
(The B23 is equipped with a highly collimated microbeam allowing the use of small aperture 349 
long path length microcuvettes6-9). SRCD measurements were carried out using 0.01 µM 350 
sample of soluble LPH-51 in a 1 cm path length cell of 3 mm aperture diameter using a 351 
Module B instrument with 1 nm increment, 1 s integration time and 1.2 nm bandwidth at 23 352 
°C. The cuvette capacity was 60 µl. Titration experiments were conducted as described 353 
previously3 using standard far-UV measurements.  354 
Statistical analysis 355 
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Each experiment was performed at least three times and statistical analysis was conducted 356 
using a two-tailed Student's t-test, where appropriate. Multiple comparisons were performed 357 
using an ANOVA test. Post-hoc Bonferroni correction was applied. Statistical probabilities 358 
(p) were expressed as * where p<0.05; **, p<0.01 and *** when p<0.001. Coefficient of 359 
determination (R2) was calculated using GraphPad Prism software in order to assess 360 
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Supplementary figure 1. Comparative analysis of LPHN1 protein expression in primary 415 
human AML, THP-1 cells and PHL. Lysates of each cell type were subjected to Western 416 
blot analysis as outlined in the Materials and Methods. Images are from one experiment 417 
representative of three which gave similar results. Data represent mean values ± SEM of 418 













Supplementary figure 2. Cell surface detection of LPHN1. Wild type NB2A cells 430 
(negative control) and THP-1 cells were subjected to an on-cell assay using anti-rabbit Li-Cor 431 
secondary antibody. Images are from one experiment representative of three which gave 432 























Supplementary figure 3. Physiological cross-links leading to cortisol-induced 454 
upregulation of LPHN1 expression in AML cells followed by facilitation of galectin-9 455 
secretion in a FLRT3-dependent manner. AML is associated with a decreased blood 456 
plasma glucose levels, which normally leads to upregulation of secretion of corticotropin-457 
releasing hormone (CTRH) by hypothalamus. CTRH induces secretion of adrenocorticotropic 458 
hormone (ACTH) by pituitary gland. Secreted ACTH upregulates cortisol production by the 459 
adrenal cortex, thus leading to cortisol-induced upregulation of LPHN1 levels in AML cells. 460 
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Galectin-9, secreted in FLRT3-LPHN1-dependent manner attenuates anti-cancer activity of 461 
cytotoxic T cells (CTC) and NK cells. 462 
 463 
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